Brand/Generic Deals Stay In FTC’s Crosshairs As It Seeks Legal Ammunition
Executive Summary
The Federal Trade Commission will not remain complacent as brand and generic companies accelerate the pace and expand the boundaries of settlements, Commissioner Jon Leibowitz said
You may also be interested in...
Brand/Generic Settlement Reform Will Be Balancing Act For Congress
Development of legislation to address settlements between brand and generic companies will need to ensure that commercial incentives remain for generic firms to challenge patents
Brand/Generic Settlement Reform Will Be Balancing Act For Congress
Development of legislation to address settlements between brand and generic companies will need to ensure that commercial incentives remain for generic firms to challenge patents
FTC Commissioner Urges Generic Firms To Shun Reverse Payment Deals
The generic industry should refrain from entering into settlement agreements with brand companies that involve payments to keep generics off the market, Federal Trade Commissioner Jon Leibowitz said at the Generic Pharmaceutical Association's Annual Policy Conference in Washington, D.C. Sept. 19